| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 167 | 2024 | 889 | 21.710 |
Why?
|
| Transplantation Conditioning | 92 | 2024 | 373 | 13.760 |
Why?
|
| Graft vs Host Disease | 77 | 2024 | 358 | 13.270 |
Why?
|
| Cord Blood Stem Cell Transplantation | 29 | 2024 | 91 | 11.450 |
Why?
|
| Transplantation, Homologous | 112 | 2024 | 995 | 7.860 |
Why?
|
| Hematologic Neoplasms | 35 | 2023 | 344 | 6.530 |
Why?
|
| Lymphoma | 28 | 2021 | 266 | 5.370 |
Why?
|
| Lymphoma, Non-Hodgkin | 33 | 2024 | 261 | 4.910 |
Why?
|
| Bone Marrow Transplantation | 47 | 2019 | 284 | 4.390 |
Why?
|
| Leukemia, Myeloid, Acute | 26 | 2024 | 799 | 3.880 |
Why?
|
| Lymphoma, Follicular | 16 | 2018 | 73 | 3.400 |
Why?
|
| Fetal Blood | 15 | 2024 | 93 | 3.280 |
Why?
|
| Stem Cell Transplantation | 20 | 2019 | 189 | 3.180 |
Why?
|
| Melphalan | 19 | 2020 | 98 | 3.160 |
Why?
|
| Unrelated Donors | 13 | 2024 | 45 | 3.110 |
Why?
|
| Transplantation, Autologous | 50 | 2024 | 348 | 3.080 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 12 | 2018 | 65 | 2.980 |
Why?
|
| Vidarabine | 17 | 2020 | 144 | 2.800 |
Why?
|
| Myelodysplastic Syndromes | 19 | 2018 | 360 | 2.690 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2020 | 1355 | 2.620 |
Why?
|
| Humans | 316 | 2024 | 90014 | 2.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2023 | 2507 | 2.330 |
Why?
|
| Graft Survival | 24 | 2024 | 908 | 2.140 |
Why?
|
| Antibodies, Neoplasm | 9 | 2011 | 84 | 2.110 |
Why?
|
| Middle Aged | 175 | 2024 | 26173 | 2.060 |
Why?
|
| Adult | 179 | 2024 | 26836 | 2.020 |
Why?
|
| Haplotypes | 7 | 2019 | 637 | 2.000 |
Why?
|
| HLA Antigens | 12 | 2018 | 227 | 1.970 |
Why?
|
| Multiple Myeloma | 16 | 2019 | 334 | 1.950 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2024 | 55 | 1.930 |
Why?
|
| Transplantation Chimera | 10 | 2016 | 81 | 1.880 |
Why?
|
| Leukemia | 18 | 2019 | 322 | 1.850 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2023 | 198 | 1.830 |
Why?
|
| Antibodies, Monoclonal | 15 | 2020 | 1396 | 1.830 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 12 | 2024 | 154 | 1.820 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 111 | 1.800 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 13 | 2018 | 50 | 1.740 |
Why?
|
| Recurrence | 49 | 2017 | 1147 | 1.720 |
Why?
|
| Anemia, Sickle Cell | 6 | 2023 | 144 | 1.710 |
Why?
|
| Male | 178 | 2024 | 42706 | 1.700 |
Why?
|
| Aged | 100 | 2024 | 19272 | 1.670 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2017 | 159 | 1.660 |
Why?
|
| Survival Analysis | 40 | 2017 | 1497 | 1.650 |
Why?
|
| Female | 182 | 2024 | 46618 | 1.600 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2018 | 305 | 1.590 |
Why?
|
| Chimerism | 6 | 2020 | 37 | 1.560 |
Why?
|
| Adenine Nucleotides | 5 | 2016 | 63 | 1.560 |
Why?
|
| Arabinonucleosides | 5 | 2016 | 39 | 1.550 |
Why?
|
| Whole-Body Irradiation | 11 | 2020 | 66 | 1.540 |
Why?
|
| Hodgkin Disease | 13 | 2014 | 181 | 1.500 |
Why?
|
| Primary Myelofibrosis | 6 | 2024 | 67 | 1.490 |
Why?
|
| Treatment Outcome | 76 | 2024 | 8292 | 1.480 |
Why?
|
| Antigens, CD34 | 15 | 2024 | 159 | 1.480 |
Why?
|
| Immunosuppressive Agents | 21 | 2019 | 979 | 1.480 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2020 | 174 | 1.470 |
Why?
|
| Tissue Donors | 20 | 2024 | 505 | 1.470 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 16 | 2021 | 166 | 1.440 |
Why?
|
| Myeloablative Agonists | 10 | 2019 | 36 | 1.420 |
Why?
|
| Salvage Therapy | 17 | 2021 | 230 | 1.400 |
Why?
|
| Histocompatibility Testing | 17 | 2019 | 137 | 1.370 |
Why?
|
| Cryopreservation | 5 | 2018 | 70 | 1.340 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2019 | 86 | 1.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2021 | 952 | 1.270 |
Why?
|
| Neutropenia | 10 | 2020 | 214 | 1.250 |
Why?
|
| Cytomegalovirus Infections | 6 | 2020 | 150 | 1.220 |
Why?
|
| Viremia | 3 | 2021 | 49 | 1.220 |
Why?
|
| Lymphoma, B-Cell | 3 | 2024 | 107 | 1.190 |
Why?
|
| Virus Activation | 3 | 2019 | 42 | 1.170 |
Why?
|
| Lymphocyte Depletion | 9 | 2017 | 98 | 1.140 |
Why?
|
| Busulfan | 12 | 2020 | 41 | 1.130 |
Why?
|
| Young Adult | 42 | 2024 | 6418 | 1.120 |
Why?
|
| Remission Induction | 27 | 2020 | 741 | 1.110 |
Why?
|
| Allografts | 12 | 2021 | 184 | 1.090 |
Why?
|
| Disease-Free Survival | 35 | 2019 | 1169 | 1.080 |
Why?
|
| Alemtuzumab | 13 | 2020 | 88 | 1.050 |
Why?
|
| Rituximab | 8 | 2019 | 117 | 1.020 |
Why?
|
| Adolescent | 66 | 2021 | 9347 | 1.020 |
Why?
|
| Survival Rate | 30 | 2019 | 1899 | 0.990 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 2331 | 0.950 |
Why?
|
| Cyclophosphamide | 16 | 2023 | 301 | 0.950 |
Why?
|
| Leukemia, Myeloid | 5 | 2016 | 249 | 0.930 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2023 | 1 | 0.890 |
Why?
|
| Combined Modality Therapy | 35 | 2020 | 1704 | 0.880 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 399 | 0.850 |
Why?
|
| Antineoplastic Agents, Alkylating | 7 | 2006 | 135 | 0.840 |
Why?
|
| Photopheresis | 4 | 2017 | 12 | 0.840 |
Why?
|
| Prognosis | 27 | 2020 | 3800 | 0.820 |
Why?
|
| Graft vs Tumor Effect | 4 | 2011 | 24 | 0.810 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 4 | 2023 | 30 | 0.800 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2013 | 11 | 0.800 |
Why?
|
| Tacrolimus | 8 | 2019 | 369 | 0.790 |
Why?
|
| Transplant Recipients | 6 | 2021 | 142 | 0.760 |
Why?
|
| Retrospective Studies | 35 | 2023 | 9237 | 0.700 |
Why?
|
| Thrombotic Microangiopathies | 4 | 2022 | 21 | 0.680 |
Why?
|
| Premedication | 5 | 2017 | 57 | 0.680 |
Why?
|
| Haploidy | 2 | 2016 | 32 | 0.670 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 233 | 0.650 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 204 | 0.650 |
Why?
|
| Herpesvirus 4, Human | 4 | 2024 | 120 | 0.640 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 414 | 0.630 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 317 | 0.630 |
Why?
|
| Risk Factors | 23 | 2019 | 5562 | 0.610 |
Why?
|
| Incidence | 13 | 2019 | 1604 | 0.610 |
Why?
|
| Transplantation, Haploidentical | 5 | 2024 | 28 | 0.610 |
Why?
|
| Cyclosporine | 5 | 2012 | 238 | 0.610 |
Why?
|
| Infusion Pumps | 1 | 2017 | 25 | 0.600 |
Why?
|
| Lymphocyte Transfusion | 5 | 2011 | 41 | 0.590 |
Why?
|
| Thrombocytopenia | 8 | 2020 | 187 | 0.590 |
Why?
|
| Regenerative Medicine | 2 | 2014 | 25 | 0.580 |
Why?
|
| Neutrophils | 5 | 2019 | 311 | 0.560 |
Why?
|
| Graft Rejection | 6 | 2017 | 1076 | 0.560 |
Why?
|
| Ganciclovir | 4 | 2006 | 49 | 0.540 |
Why?
|
| Antilymphocyte Serum | 2 | 2021 | 70 | 0.540 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 7 | 0.530 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 856 | 0.530 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 19 | 0.520 |
Why?
|
| Radiation Dosage | 1 | 2017 | 230 | 0.510 |
Why?
|
| T-Lymphocytes | 8 | 2023 | 1221 | 0.510 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2018 | 19 | 0.510 |
Why?
|
| Piperazines | 3 | 2020 | 283 | 0.510 |
Why?
|
| Hematopoiesis | 7 | 2016 | 168 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 606 | 0.490 |
Why?
|
| Interleukin-2 | 6 | 2010 | 241 | 0.490 |
Why?
|
| Acute Disease | 17 | 2016 | 846 | 0.490 |
Why?
|
| Histocompatibility | 6 | 2016 | 65 | 0.480 |
Why?
|
| Follow-Up Studies | 19 | 2019 | 3684 | 0.470 |
Why?
|
| Prospective Studies | 17 | 2024 | 4329 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 586 | 0.470 |
Why?
|
| Time Factors | 16 | 2018 | 5361 | 0.470 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 338 | 0.460 |
Why?
|
| Pyrimidines | 3 | 2019 | 371 | 0.460 |
Why?
|
| Antiviral Agents | 5 | 2020 | 482 | 0.460 |
Why?
|
| Acyclovir | 2 | 2006 | 108 | 0.460 |
Why?
|
| Lymphopoiesis | 1 | 2014 | 48 | 0.450 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 38 | 0.450 |
Why?
|
| Mycophenolic Acid | 5 | 2019 | 84 | 0.450 |
Why?
|
| Skin Diseases | 2 | 2012 | 174 | 0.440 |
Why?
|
| Thalidomide | 4 | 2017 | 55 | 0.440 |
Why?
|
| Bone Marrow Diseases | 2 | 2013 | 40 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2023 | 2677 | 0.430 |
Why?
|
| Ferritins | 1 | 2013 | 29 | 0.420 |
Why?
|
| Anemia, Aplastic | 3 | 2006 | 32 | 0.410 |
Why?
|
| Donor Selection | 1 | 2013 | 77 | 0.400 |
Why?
|
| Heterocyclic Compounds | 4 | 2018 | 17 | 0.400 |
Why?
|
| Clinical Trials as Topic | 10 | 2018 | 1134 | 0.390 |
Why?
|
| Self Report | 2 | 2012 | 297 | 0.390 |
Why?
|
| Age Factors | 9 | 2018 | 1880 | 0.380 |
Why?
|
| Leukocyte Transfusion | 2 | 2010 | 15 | 0.380 |
Why?
|
| Decision Trees | 1 | 2011 | 61 | 0.370 |
Why?
|
| Myasthenia Gravis | 1 | 2011 | 83 | 0.370 |
Why?
|
| Fatal Outcome | 5 | 2011 | 296 | 0.360 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 97 | 0.360 |
Why?
|
| Azacitidine | 4 | 2024 | 148 | 0.360 |
Why?
|
| Carmustine | 4 | 2006 | 70 | 0.350 |
Why?
|
| Karnofsky Performance Status | 4 | 2009 | 39 | 0.340 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 201 | 0.340 |
Why?
|
| Vidarabine Phosphate | 1 | 2009 | 5 | 0.330 |
Why?
|
| Ifosfamide | 5 | 2004 | 48 | 0.330 |
Why?
|
| BK Virus | 1 | 2009 | 24 | 0.330 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 740 | 0.330 |
Why?
|
| Mediastinal Neoplasms | 2 | 2001 | 46 | 0.330 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2023 | 395 | 0.330 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 29 | 0.330 |
Why?
|
| Bacteremia | 3 | 2021 | 103 | 0.320 |
Why?
|
| Hematuria | 1 | 2009 | 50 | 0.320 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 83 | 0.320 |
Why?
|
| Patient Selection | 7 | 2007 | 682 | 0.320 |
Why?
|
| Leukemia, Lymphoid | 2 | 2012 | 72 | 0.310 |
Why?
|
| Pneumonia | 2 | 2010 | 183 | 0.310 |
Why?
|
| Renal Dialysis | 1 | 2011 | 338 | 0.310 |
Why?
|
| Alleles | 5 | 2016 | 1137 | 0.310 |
Why?
|
| Interleukin-6 | 2 | 2008 | 264 | 0.310 |
Why?
|
| Lymphocyte Count | 3 | 2021 | 99 | 0.300 |
Why?
|
| Thiotepa | 7 | 2003 | 32 | 0.300 |
Why?
|
| Calcineurin Inhibitors | 2 | 2011 | 53 | 0.300 |
Why?
|
| Fever | 2 | 2020 | 127 | 0.300 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 192 | 0.290 |
Why?
|
| Imatinib Mesylate | 3 | 2020 | 126 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 855 | 0.280 |
Why?
|
| Mycoses | 1 | 2007 | 46 | 0.280 |
Why?
|
| Dendritic Cells | 2 | 2009 | 451 | 0.280 |
Why?
|
| Kidney Diseases | 2 | 2009 | 320 | 0.280 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 785 | 0.270 |
Why?
|
| Dacarbazine | 2 | 2007 | 101 | 0.270 |
Why?
|
| Blood Donors | 3 | 2016 | 22 | 0.270 |
Why?
|
| Siblings | 8 | 2014 | 110 | 0.270 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 107 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2011 | 76 | 0.260 |
Why?
|
| Child | 21 | 2018 | 7242 | 0.260 |
Why?
|
| Graft vs Host Reaction | 3 | 2009 | 15 | 0.260 |
Why?
|
| Valine | 1 | 2006 | 62 | 0.260 |
Why?
|
| Mortality | 3 | 2016 | 149 | 0.260 |
Why?
|
| Isoantibodies | 2 | 2018 | 120 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2006 | 333 | 0.250 |
Why?
|
| Blood Cell Count | 6 | 2016 | 79 | 0.250 |
Why?
|
| Sarcoma | 1 | 2007 | 219 | 0.250 |
Why?
|
| Etoposide | 9 | 2004 | 206 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2016 | 2316 | 0.240 |
Why?
|
| Methotrexate | 4 | 2019 | 243 | 0.240 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 2 | 2022 | 2 | 0.230 |
Why?
|
| Cytarabine | 7 | 2013 | 219 | 0.230 |
Why?
|
| Iodine Radioisotopes | 1 | 2024 | 134 | 0.230 |
Why?
|
| Microvessels | 2 | 2022 | 69 | 0.220 |
Why?
|
| Vaccination | 2 | 2022 | 279 | 0.220 |
Why?
|
| Glioblastoma | 1 | 2006 | 268 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2013 | 1929 | 0.220 |
Why?
|
| Natural Killer T-Cells | 1 | 2024 | 45 | 0.220 |
Why?
|
| Immunotherapy | 4 | 2020 | 699 | 0.220 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 6787 | 0.220 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2020 | 37 | 0.210 |
Why?
|
| Vancomycin | 3 | 2020 | 73 | 0.210 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 38 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2003 | 32 | 0.210 |
Why?
|
| Levofloxacin | 2 | 2021 | 8 | 0.210 |
Why?
|
| Oxides | 1 | 2003 | 43 | 0.210 |
Why?
|
| Arsenicals | 1 | 2003 | 48 | 0.210 |
Why?
|
| Thorax | 1 | 2023 | 77 | 0.210 |
Why?
|
| Disease Progression | 7 | 2016 | 1469 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 44 | 0.200 |
Why?
|
| HIV-1 | 1 | 2023 | 164 | 0.200 |
Why?
|
| Leukocyte Count | 4 | 2019 | 224 | 0.200 |
Why?
|
| Geriatric Assessment | 2 | 2014 | 182 | 0.200 |
Why?
|
| Organ Transplantation | 3 | 2024 | 283 | 0.190 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2019 | 11 | 0.190 |
Why?
|
| Medical Oncology | 2 | 2020 | 384 | 0.190 |
Why?
|
| Child, Preschool | 9 | 2018 | 3773 | 0.190 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 1991 | 15 | 0.190 |
Why?
|
| Antioxidants | 1 | 2003 | 226 | 0.190 |
Why?
|
| Cell Survival | 3 | 2019 | 983 | 0.190 |
Why?
|
| Bone Marrow | 8 | 2022 | 443 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 450 | 0.190 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2014 | 51 | 0.190 |
Why?
|
| Injections, Subcutaneous | 2 | 2024 | 122 | 0.190 |
Why?
|
| Precision Medicine | 2 | 2019 | 413 | 0.180 |
Why?
|
| Splenomegaly | 2 | 2016 | 28 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 523 | 0.180 |
Why?
|
| Bortezomib | 2 | 2018 | 80 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2019 | 600 | 0.180 |
Why?
|
| Oncology Service, Hospital | 1 | 2020 | 6 | 0.180 |
Why?
|
| Prednisone | 4 | 2023 | 255 | 0.180 |
Why?
|
| Dibenzothiepins | 1 | 2020 | 1 | 0.180 |
Why?
|
| Trophoblastic Neoplasms | 2 | 1997 | 5 | 0.180 |
Why?
|
| Risk | 5 | 2013 | 657 | 0.180 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2020 | 26 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2020 | 30 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 644 | 0.180 |
Why?
|
| Oseltamivir | 1 | 2020 | 20 | 0.180 |
Why?
|
| Adenoviridae | 1 | 2021 | 349 | 0.180 |
Why?
|
| Registries | 8 | 2009 | 808 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1545 | 0.170 |
Why?
|
| Hematology | 1 | 2020 | 30 | 0.170 |
Why?
|
| Adult Stem Cells | 2 | 2011 | 29 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 799 | 0.170 |
Why?
|
| Length of Stay | 2 | 2017 | 749 | 0.170 |
Why?
|
| Morpholines | 1 | 2020 | 70 | 0.170 |
Why?
|
| Pyridones | 1 | 2020 | 56 | 0.170 |
Why?
|
| Blood Platelets | 2 | 2018 | 150 | 0.170 |
Why?
|
| Triazines | 1 | 2020 | 54 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 158 | 0.170 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 60 | 0.170 |
Why?
|
| Comorbidity | 3 | 2016 | 953 | 0.170 |
Why?
|
| Freedom | 1 | 2019 | 18 | 0.170 |
Why?
|
| Janus Kinase 3 | 1 | 2019 | 9 | 0.170 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 4 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 74 | 0.160 |
Why?
|
| Pilot Projects | 7 | 2012 | 872 | 0.160 |
Why?
|
| Familial Mediterranean Fever | 1 | 2019 | 4 | 0.160 |
Why?
|
| Blood Preservation | 2 | 2015 | 10 | 0.160 |
Why?
|
| New York | 1 | 2019 | 73 | 0.160 |
Why?
|
| Enterobacteriaceae | 1 | 2018 | 22 | 0.160 |
Why?
|
| Motivation | 1 | 2021 | 296 | 0.160 |
Why?
|
| Administration, Intravenous | 2 | 2015 | 56 | 0.160 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 24 | 0.160 |
Why?
|
| Proportional Hazards Models | 6 | 2009 | 848 | 0.160 |
Why?
|
| Cryoprotective Agents | 1 | 2018 | 9 | 0.150 |
Why?
|
| Coronavirus | 1 | 2018 | 18 | 0.150 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2018 | 38 | 0.150 |
Why?
|
| Multivariate Analysis | 10 | 2013 | 983 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 65 | 0.150 |
Why?
|
| Mycobacterium avium Complex | 1 | 2018 | 6 | 0.150 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2018 | 9 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2019 | 150 | 0.150 |
Why?
|
| Pyrroles | 1 | 2019 | 172 | 0.150 |
Why?
|
| Blood Component Removal | 4 | 2015 | 24 | 0.150 |
Why?
|
| Piperidines | 1 | 2019 | 163 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 27 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 486 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2018 | 239 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2019 | 301 | 0.140 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2017 | 17 | 0.140 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2010 | 71 | 0.140 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 48 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2010 | 278 | 0.140 |
Why?
|
| Ribavirin | 1 | 2017 | 40 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2020 | 464 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2020 | 340 | 0.140 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 66 | 0.140 |
Why?
|
| Mastocytosis | 1 | 2016 | 13 | 0.130 |
Why?
|
| Respirovirus | 1 | 2016 | 4 | 0.130 |
Why?
|
| Lactate Dehydrogenases | 1 | 2016 | 1 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2014 | 338 | 0.130 |
Why?
|
| Paramyxoviridae Infections | 1 | 2016 | 5 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2018 | 122 | 0.130 |
Why?
|
| Neoplasms | 3 | 2024 | 3067 | 0.130 |
Why?
|
| Mice | 5 | 2023 | 11859 | 0.130 |
Why?
|
| Genotype | 2 | 2019 | 1852 | 0.130 |
Why?
|
| Lung | 1 | 2023 | 1292 | 0.130 |
Why?
|
| Blood Component Transfusion | 1 | 2015 | 13 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 151 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2014 | 2887 | 0.130 |
Why?
|
| Living Donors | 2 | 2009 | 339 | 0.130 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2011 | 16 | 0.130 |
Why?
|
| Picornaviridae Infections | 1 | 2015 | 7 | 0.130 |
Why?
|
| Rhinovirus | 1 | 2015 | 25 | 0.130 |
Why?
|
| Erythrocytes | 3 | 2015 | 254 | 0.130 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 66 | 0.130 |
Why?
|
| Mutation | 3 | 2019 | 4169 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2018 | 197 | 0.120 |
Why?
|
| Stem Cell Factor | 2 | 2012 | 19 | 0.120 |
Why?
|
| Toxoplasma | 1 | 2016 | 116 | 0.120 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2015 | 6 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 528 | 0.120 |
Why?
|
| Cell Lineage | 1 | 2016 | 293 | 0.120 |
Why?
|
| Cause of Death | 5 | 2009 | 269 | 0.120 |
Why?
|
| Dextrans | 1 | 2015 | 79 | 0.120 |
Why?
|
| Chronic Disease | 7 | 2010 | 958 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.120 |
Why?
|
| Cell Count | 1 | 2015 | 199 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 426 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2010 | 111 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 1997 | 784 | 0.120 |
Why?
|
| Benzylamines | 4 | 2018 | 17 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2014 | 16 | 0.120 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2014 | 14 | 0.110 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 2001 | 8 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 3 | 2012 | 260 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 189 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 563 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 115 | 0.110 |
Why?
|
| HIV Infections | 1 | 2023 | 847 | 0.110 |
Why?
|
| Hematologic Diseases | 3 | 2015 | 78 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 166 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2018 | 305 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 101 | 0.110 |
Why?
|
| Transplants | 1 | 2014 | 42 | 0.110 |
Why?
|
| Neoplasm, Residual | 4 | 2011 | 181 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 152 | 0.110 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2013 | 1 | 0.110 |
Why?
|
| Immunoconjugates | 2 | 2024 | 114 | 0.110 |
Why?
|
| Illinois | 2 | 2012 | 485 | 0.110 |
Why?
|
| HLA-DR Antigens | 4 | 2000 | 59 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2007 | 449 | 0.110 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.110 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 148 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.110 |
Why?
|
| HLA-DP Antigens | 1 | 2013 | 8 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 12 | 0.110 |
Why?
|
| Benzamides | 2 | 2011 | 234 | 0.110 |
Why?
|
| Daunorubicin | 1 | 2013 | 78 | 0.110 |
Why?
|
| Biomarkers | 2 | 2019 | 1778 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 48 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1863 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 1997 | 250 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2013 | 60 | 0.100 |
Why?
|
| Quality of Life | 3 | 2018 | 1682 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 2012 | 33 | 0.100 |
Why?
|
| Polychondritis, Relapsing | 1 | 1992 | 5 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 51 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2013 | 99 | 0.100 |
Why?
|
| Erythropoietin | 1 | 2012 | 90 | 0.100 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2012 | 6 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2010 | 2000 | 0.100 |
Why?
|
| 2-Chloroadenosine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Pyridostigmine Bromide | 1 | 2011 | 11 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 919 | 0.100 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2011 | 9 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 11 | 0.100 |
Why?
|
| Deoxyadenosines | 1 | 2011 | 23 | 0.100 |
Why?
|
| Animals | 6 | 2023 | 27537 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 263 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 665 | 0.100 |
Why?
|
| Heparinoids | 1 | 1991 | 4 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2022 | 153 | 0.090 |
Why?
|
| Dermatan Sulfate | 1 | 1991 | 9 | 0.090 |
Why?
|
| Genetic Therapy | 1 | 2014 | 372 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 1991 | 27 | 0.090 |
Why?
|
| Recombinant Proteins | 11 | 2009 | 1008 | 0.090 |
Why?
|
| Feasibility Studies | 7 | 2009 | 785 | 0.090 |
Why?
|
| Glycosaminoglycans | 1 | 1991 | 47 | 0.090 |
Why?
|
| Chondroitin Sulfates | 1 | 1991 | 43 | 0.090 |
Why?
|
| Morbidity | 1 | 2011 | 149 | 0.090 |
Why?
|
| Infant | 3 | 2018 | 3189 | 0.090 |
Why?
|
| CD3 Complex | 2 | 2009 | 134 | 0.090 |
Why?
|
| Pneumonia, Viral | 1 | 2016 | 319 | 0.090 |
Why?
|
| Education | 1 | 2011 | 58 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 120 | 0.090 |
Why?
|
| Data Collection | 4 | 2009 | 377 | 0.090 |
Why?
|
| Random Allocation | 1 | 2011 | 327 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 522 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 181 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 277 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 163 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2010 | 203 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 387 | 0.090 |
Why?
|
| Heparin | 1 | 1991 | 185 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 841 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 1991 | 66 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 101 | 0.080 |
Why?
|
| Bone Marrow Purging | 2 | 2006 | 7 | 0.080 |
Why?
|
| Nuclear Family | 2 | 2000 | 93 | 0.080 |
Why?
|
| Sirolimus | 1 | 2010 | 162 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 266 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2010 | 115 | 0.080 |
Why?
|
| Drug Administration Schedule | 8 | 2013 | 865 | 0.080 |
Why?
|
| Diarrhea | 3 | 2020 | 178 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 591 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 521 | 0.080 |
Why?
|
| Vancomycin Resistance | 1 | 2008 | 18 | 0.080 |
Why?
|
| Age Distribution | 1 | 2009 | 199 | 0.080 |
Why?
|
| Enterococcus | 1 | 2008 | 35 | 0.080 |
Why?
|
| Antigens, CD | 4 | 2003 | 466 | 0.080 |
Why?
|
| New York City | 2 | 2020 | 61 | 0.080 |
Why?
|
| HLA-DQ Antigens | 2 | 2000 | 51 | 0.080 |
Why?
|
| Leukocytosis | 1 | 2008 | 16 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 294 | 0.080 |
Why?
|
| Antifungal Agents | 2 | 2007 | 123 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2008 | 23 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1732 | 0.080 |
Why?
|
| Osteopontin | 1 | 2008 | 47 | 0.070 |
Why?
|
| Self Tolerance | 1 | 2007 | 25 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 109 | 0.070 |
Why?
|
| Cisplatin | 4 | 1999 | 598 | 0.070 |
Why?
|
| Cell Separation | 4 | 2015 | 199 | 0.070 |
Why?
|
| Cross Infection | 1 | 2008 | 151 | 0.070 |
Why?
|
| Health Status | 1 | 2009 | 371 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2007 | 96 | 0.070 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 21 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 178 | 0.070 |
Why?
|
| Industry | 1 | 2007 | 18 | 0.070 |
Why?
|
| History, 19th Century | 1 | 2007 | 56 | 0.070 |
Why?
|
| Filgrastim | 5 | 2009 | 57 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 303 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2008 | 242 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1913 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 277 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2008 | 195 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2023 | 171 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2007 | 85 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2007 | 52 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2023 | 293 | 0.070 |
Why?
|
| Hospitals, Special | 1 | 2005 | 7 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2007 | 185 | 0.060 |
Why?
|
| Intestinal Diseases | 1 | 2006 | 79 | 0.060 |
Why?
|
| Pain | 1 | 2008 | 400 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2007 | 315 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 250 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 174 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1714 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2007 | 468 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 1066 | 0.060 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.060 |
Why?
|
| Actins | 1 | 2008 | 462 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2005 | 149 | 0.060 |
Why?
|
| Karyopherins | 1 | 2024 | 15 | 0.060 |
Why?
|
| Hydrazines | 1 | 2024 | 31 | 0.060 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.060 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 142 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2024 | 78 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 18 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2019 | 160 | 0.050 |
Why?
|
| Pregnancy | 4 | 1997 | 3046 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2024 | 122 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 194 | 0.050 |
Why?
|
| Vincristine | 1 | 2023 | 111 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2007 | 550 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2360 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1868 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2006 | 776 | 0.050 |
Why?
|
| Cell Division | 2 | 2002 | 692 | 0.050 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2022 | 21 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 351 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cytokines | 3 | 2024 | 811 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2002 | 69 | 0.050 |
Why?
|
| Megakaryocytes | 3 | 1992 | 36 | 0.050 |
Why?
|
| Antineoplastic Protocols | 1 | 2002 | 9 | 0.050 |
Why?
|
| Thrombosis | 1 | 2005 | 302 | 0.050 |
Why?
|
| MEDLINE | 1 | 2001 | 8 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 374 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2021 | 22 | 0.050 |
Why?
|
| United States | 6 | 2011 | 7114 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 198 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 2327 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 1184 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 27 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1606 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 346 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 2588 | 0.050 |
Why?
|
| Mitoxantrone | 2 | 2012 | 67 | 0.050 |
Why?
|
| Cells, Cultured | 5 | 2018 | 2887 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 77 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 35 | 0.050 |
Why?
|
| Hematopoietic System | 1 | 2020 | 13 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 23 | 0.040 |
Why?
|
| Patient Isolation | 1 | 2020 | 14 | 0.040 |
Why?
|
| Melanoma | 1 | 2005 | 471 | 0.040 |
Why?
|
| Family | 2 | 2012 | 324 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2020 | 27 | 0.040 |
Why?
|
| Foscarnet | 2 | 1997 | 12 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2020 | 48 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2011 | 72 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 2 | 1990 | 14 | 0.040 |
Why?
|
| Age of Onset | 1 | 2001 | 318 | 0.040 |
Why?
|
| Growth Substances | 2 | 1990 | 79 | 0.040 |
Why?
|
| Gentamicins | 1 | 1999 | 20 | 0.040 |
Why?
|
| Immune Tolerance | 2 | 2014 | 341 | 0.040 |
Why?
|
| Deoxycytidine | 2 | 2013 | 211 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2019 | 109 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 972 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 476 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1983 | 0.040 |
Why?
|
| Colchicine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 20 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2018 | 13 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 2018 | 28 | 0.040 |
Why?
|
| Granulocytes | 2 | 2015 | 38 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 333 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2001 | 262 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 700 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 156 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 67 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 76 | 0.040 |
Why?
|
| Antisickling Agents | 1 | 2018 | 4 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2018 | 151 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2018 | 56 | 0.040 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2018 | 9 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 515 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 728 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2018 | 54 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2024 | 2026 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1055 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 2 | 2015 | 40 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 306 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 3404 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2017 | 18 | 0.040 |
Why?
|
| Telemedicine | 1 | 2020 | 195 | 0.040 |
Why?
|
| Cell Differentiation | 4 | 2012 | 1533 | 0.040 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2017 | 26 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1534 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 646 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 295 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 211 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2018 | 118 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1091 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 192 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 461 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1997 | 41 | 0.030 |
Why?
|
| Hemorrhage | 2 | 1995 | 287 | 0.030 |
Why?
|
| Parasitemia | 1 | 2016 | 6 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 251 | 0.030 |
Why?
|
| Unsupervised Machine Learning | 1 | 2016 | 6 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 39 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2016 | 77 | 0.030 |
Why?
|
| Carboprost | 1 | 1995 | 3 | 0.030 |
Why?
|
| Cystitis | 1 | 1995 | 14 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 1130 | 0.030 |
Why?
|
| Decision Making | 1 | 2001 | 671 | 0.030 |
Why?
|
| Sequence Homology | 1 | 2015 | 28 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 126 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 2015 | 19 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2015 | 690 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2001 | 3022 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 159 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 1995 | 16 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 145 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 54 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 321 | 0.030 |
Why?
|
| Stem Cells | 1 | 1997 | 376 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2015 | 17 | 0.030 |
Why?
|
| Bone Marrow Cells | 3 | 1990 | 262 | 0.030 |
Why?
|
| Electrolytes | 1 | 2015 | 52 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 182 | 0.030 |
Why?
|
| Citric Acid | 1 | 2015 | 44 | 0.030 |
Why?
|
| Chicago | 2 | 2010 | 1434 | 0.030 |
Why?
|
| Hemolysis | 1 | 2015 | 64 | 0.030 |
Why?
|
| Platelet Count | 2 | 1992 | 93 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 158 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 307 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1666 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 371 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 969 | 0.030 |
Why?
|
| Sinusitis | 1 | 1997 | 216 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2012 | 1670 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1995 | 186 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 366 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1994 | 79 | 0.030 |
Why?
|
| Biological Factors | 2 | 1990 | 18 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 113 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 1999 | 416 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 54 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 667 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 13 | 0.030 |
Why?
|
| Pyrazines | 1 | 2013 | 91 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2012 | 81 | 0.030 |
Why?
|
| Telomerase | 1 | 2012 | 67 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1214 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 45 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 160 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2012 | 80 | 0.020 |
Why?
|
| Glucose | 1 | 2015 | 629 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 156 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 869 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2012 | 84 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 268 | 0.020 |
Why?
|
| Life Tables | 2 | 2006 | 47 | 0.020 |
Why?
|
| Models, Biological | 2 | 2009 | 1766 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 205 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 755 | 0.020 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1991 | 8 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 1991 | 46 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 131 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1991 | 20 | 0.020 |
Why?
|
| Mental Health | 1 | 2012 | 180 | 0.020 |
Why?
|
| Parvoviridae | 1 | 1990 | 3 | 0.020 |
Why?
|
| Preleukemia | 1 | 1990 | 11 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1991 | 193 | 0.020 |
Why?
|
| Mucositis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Reticulocytes | 1 | 1990 | 25 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 384 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 168 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1243 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 387 | 0.020 |
Why?
|
| Group Processes | 1 | 2010 | 31 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 142 | 0.020 |
Why?
|
| Interleukins | 1 | 1990 | 132 | 0.020 |
Why?
|
| Rationalization | 1 | 2009 | 1 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 1990 | 73 | 0.020 |
Why?
|
| Methods | 1 | 2009 | 151 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 159 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1198 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 272 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 103 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 159 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 338 | 0.020 |
Why?
|
| Sclerosing Solutions | 1 | 1988 | 5 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2008 | 12 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 234 | 0.020 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1988 | 35 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 538 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 453 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1989 | 270 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 38 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 183 | 0.020 |
Why?
|
| Blast Crisis | 2 | 1999 | 37 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 216 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 14 | 0.020 |
Why?
|
| Steroids | 1 | 2008 | 173 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1989 | 469 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 20 | 0.020 |
Why?
|
| Intellectual Property | 1 | 2007 | 3 | 0.020 |
Why?
|
| Vinblastine | 1 | 2007 | 100 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 435 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 1211 | 0.020 |
Why?
|
| Bleomycin | 1 | 2007 | 103 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Thinness | 1 | 2006 | 46 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 125 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1718 | 0.020 |
Why?
|
| Reoperation | 1 | 2008 | 605 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1988 | 239 | 0.020 |
Why?
|
| Monophenol Monooxygenase | 1 | 2005 | 9 | 0.020 |
Why?
|
| Overweight | 1 | 2006 | 119 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2007 | 162 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 30 | 0.020 |
Why?
|
| Carboplatin | 2 | 2001 | 312 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2005 | 77 | 0.020 |
Why?
|
| Intracranial Thrombosis | 1 | 2005 | 29 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 360 | 0.010 |
Why?
|
| Retroviridae | 1 | 2005 | 79 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1250 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2005 | 88 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2005 | 153 | 0.010 |
Why?
|
| Warfarin | 1 | 2005 | 104 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 110 | 0.010 |
Why?
|
| Immunophenotyping | 2 | 1995 | 217 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2005 | 135 | 0.010 |
Why?
|
| Motor Activity | 1 | 2006 | 327 | 0.010 |
Why?
|
| Aspirin | 1 | 2005 | 162 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 446 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 40 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 2016 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 125 | 0.010 |
Why?
|
| Echocardiography | 1 | 2007 | 944 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 171 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 274 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 226 | 0.010 |
Why?
|
| Infusions, Intraosseous | 1 | 2001 | 6 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 341 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 696 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1048 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2001 | 215 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2000 | 30 | 0.010 |
Why?
|
| Hearing Disorders | 1 | 1999 | 8 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1999 | 10 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 1999 | 7 | 0.010 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1999 | 7 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 1999 | 63 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
| Idarubicin | 1 | 1997 | 8 | 0.010 |
Why?
|
| Serology | 1 | 1997 | 3 | 0.010 |
Why?
|
| Cladribine | 1 | 1997 | 35 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1997 | 29 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1997 | 82 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
| X Chromosome | 1 | 1997 | 153 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 99 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 352 | 0.010 |
Why?
|
| Nausea | 1 | 1997 | 175 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1995 | 34 | 0.010 |
Why?
|
| Thy-1 Antigens | 1 | 1995 | 16 | 0.010 |
Why?
|
| Chimera | 1 | 1995 | 56 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 591 | 0.010 |
Why?
|
| Vomiting | 1 | 1997 | 195 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1994 | 8 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 1992 | 12 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1994 | 275 | 0.010 |
Why?
|
| Kidney | 1 | 1997 | 1148 | 0.010 |
Why?
|
| Thymidine | 1 | 1992 | 59 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 133 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1990 | 28 | 0.010 |
Why?
|
| Capsid | 1 | 1990 | 34 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 1990 | 8 | 0.010 |
Why?
|
| Lewis X Antigen | 1 | 1990 | 9 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1990 | 32 | 0.010 |
Why?
|
| Leukopenia | 1 | 1990 | 66 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1990 | 258 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1990 | 40 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 141 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1990 | 91 | 0.010 |
Why?
|
| DNA Replication | 1 | 1990 | 171 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1990 | 263 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1990 | 102 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1989 | 137 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 1989 | 94 | 0.010 |
Why?
|
| Virus Replication | 1 | 1990 | 326 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 996 | 0.000 |
Why?
|
| Periodicity | 1 | 1989 | 119 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1990 | 508 | 0.000 |
Why?
|
| Esophagoscopy | 1 | 1988 | 90 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 1989 | 772 | 0.000 |
Why?
|